Skip to content
Injectable Index

AestheFill

AestheFill is a reconstituted poly-D,L-lactic acid (PDLLA) injectable developed and presented by REGEN Biotech. The commonly described 200 mg vial contains 154 mg of PDLLA microspheres and 46 mg of carboxymethylcellulose (CMC). It is not the same formulation category as Juvelook, which combines PDLLA with HA.

Quick reference

Section titled “Quick reference”
FieldAestheFill
MaterialPoly-D,L-lactic acid microspheres
Commonly described vial composition154 mg PDLLA + 46 mg CMC; 200 mg total
Product formLyophilized granules or pellets in a vial
PreparationRequires reconstitution with sterile water for injection
HA componentNot the same PDLLA + HA hybrid formulation as Juvelook
Developer and product companyREGEN Biotech
Main comparisonJuvelook family; Sculptra only at a defined product level

REGEN Biotech identifies AestheFill as a PDLLA injectable for improvement of facial wrinkles and folds and explicitly notes that availability and intended use vary by country (REGEN Biotech 🔗).

The detailed 154 mg PDLLA and 46 mg CMC composition is reported in a product-specific 2025 consensus paper (Clinical, Cosmetic and Investigational Dermatology 🔗).

Formulation and physical form

Section titled “Formulation and physical form”

AestheFill is described as microporous PDLLA microspheres combined with CMC and supplied as lyophilized material requiring reconstitution. The product-specific physical form matters because it affects wetting, suspension preparation, and how morphology claims are interpreted.

Manufacturer and clinical publications describe a porous spherical architecture. That establishes a product design distinction; it does not independently prove:

  • lower nodule risk than every PLLA product
  • safer superficial placement
  • faster clinical response
  • more uniform collagen production in every patient
  • superiority over hybrid PDLLA + HA products

Comparative performance claims require compatible clinical endpoints and appropriate independent evidence.

Preparation: IFU and consensus are different sources

Section titled “Preparation: IFU and consensus are different sources”

The product requires reconstitution with sterile water for injection. A 2025 Brazilian expert consensus recommends 7–8 mL of sterile water and discusses optional lidocaine, but this is consensus guidance, not a universal regulatory label.

The same publication describes:

  • a lyophilized product form
  • 154 mg PDLLA microspheres
  • 46 mg CMC
  • product-specific reconstitution considerations
  • individualized treatment planning

Use the current local IFU for the controlling clinical instruction. When citing a consensus protocol, identify its country, panel method, product presentation, and publication date.

An earlier experimental study examined different diluents and an accelerated back-and-forth reconstitution method for AestheFill-V200 (Plastic and Reconstructive Surgery Global Open 🔗). Experimental efficiency does not automatically make every tested diluent or technique label-compliant.

AestheFill versus Juvelook

Section titled “AestheFill versus Juvelook”
FieldAestheFillJuvelook family
PolymerPDLLAPDLLA
Additional main componentCMC in the reconstituted product systemHA is explicitly listed with PDLLA
Product family structureAestheFill presentations require exact-market verificationMultiple listed PDLLA + HA quantities and product names
Immediate-effect interpretationDepends on the prepared AestheFill suspensionMust account for the HA component as well as PDLLA
Protocol transferNot supportedNot supported

This comparison explains formulation architecture. It does not establish equivalent indications, interchangeable dose, relative safety, or clinical preference.

Intended use and regional context

Section titled “Intended use and regional context”

REGEN Biotech describes improvement of facial wrinkles and folds. The company also cautions that the product may not be available in every country and that intended use varies by market.

Therefore:

  • cite the applicable registration or IFU for approval claims
  • do not turn published scar, body, or skin-quality use into universal approval
  • identify whether AestheFill refers to a specific vial presentation
  • keep local distributor claims separate from manufacturer and approval-holder roles

Immediate appearance and delayed response

Section titled “Immediate appearance and delayed response”

The prepared suspension occupies space immediately after injection, but the early water-related appearance is not the same as the later tissue response. A practitioner record should distinguish:

  • prepared suspension volume
  • initial physical correction
  • absorption of fluid
  • gradual clinical change
  • study follow-up duration

Avoid presenting the product as either purely immediate or purely delayed without specifying the phase being discussed.

Company roles

Section titled “Company roles”
RoleSupported relationship
Product development and official product sourceREGEN Biotech
BrandAestheFill
Legal manufacturerVerify from the applicable registration or IFU
Local approval holderMarket-specific
Authorized distributorMarket-specific

REGEN Biotech states that it does not authorize online sales outside local official distributors. Reseller pages should not be used to establish product identity, approval, preparation, or authenticity.

The REGEN Biotech company page connects AestheFill to the company’s polymer-development and manufacturing history.

Safety and limitations

Section titled “Safety and limitations”

AestheFill is a particulate injectable implant. Safety interpretation should account for:

  • product preparation and homogeneity
  • placement and distribution
  • anatomy and vascular risk
  • early versus delayed nodules
  • inflammatory signs
  • infection
  • regional contraindications and warnings

The product’s biodegradability does not create immediate reversibility or eliminate the possibility of vascular, inflammatory, or delayed complications.

Nearby reference pages

Section titled “Nearby reference pages”